Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2019 Sep;34(9):1620-1625.
doi: 10.1111/jgh.14615. Epub 2019 Feb 17.

Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection

Chen-Hua Liu  1   2   3 , Tung-Hung Su  1   2 , Chun-Jen Liu  1   2   4 , Chun-Ming Hong  1 , Hung-Chih Yang  1   2   5 , Tai-Chung Tseng  1   2 , Pei-Jer Chen  1   2   4 , Ding-Shinn Chen  1   2   6 , Jia-Horng Kao  1   2   4
Affiliations
Comparative Study

Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection

Chen-Hua Liu et al. J Gastroenterol Hepatol. 2019 Sep.

Abstract

Background and aim: Data regarding the comparative effectiveness and safety of sofosbuvir (SOF) in combination with ribavirin (RBV), daclatasvir (DCV), or ledipasvir (LDV) for hepatitis C virus genotype 2 (HCV-2) patients were limited. We aimed to evaluate the performance of these regimens in Taiwan.

Methods: One hundred eighty-seven HCV-2 patients with compensated liver diseases receiving SOF in combination with RBV (n = 82), DCV (n = 66), or LDV (n = 39) for 12 weeks were retrospectively enrolled. The effectiveness was determined by sustained virologic response 12 weeks off therapy (SVR12 ). The patient characteristics potentially related to SVR12 were compared. The safety profiles and laboratory abnormalities were assessed.

Results: The SVR12 rates were 93.9% (95% confidence interval [CI]: 86.5-97.4%), 98.5% (95% CI: 91.9-99.7%), and 100% (95% CI: 91.0-100%) in patients receiving SOF combined with RBV, DCV, and LDV, respectively. All patients tolerated treatment well. The stratified SVR12 rates were comparable regardless of baseline characteristics or week 4 viral decline among these regimens. Six (3.2%) patients had serious adverse events which were not related to treatment. The rates of fatigue, pruritus, and anemia tended to be higher in patients receiving RBV (22.0%, 19.5%, and 8.5%) combination than those receiving DCV (10.6%, 6.1%, and 1.5%) or LDV (10.3%, 5.1%, and 0%) combination.

Conclusions: Sofosbuvir in combination with RBV, DCV, or LDV for 12 weeks is effective and well-tolerated for HCV-2 patients. Compared with DCV or LDV combination, the risks of fatigue, pruritus, and anemia are higher in patients receiving RBV combination.

Keywords: direct acting antiviral agent; genotype 2; hepatitis C virus; sofosbuvir; sustained virologic response.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol. Hepatol. 2017; 2: 161-176.
    1. Kao JH. Hepatitis C virus infection in Taiwan: past, present, and future. J Formos Med Assoc 2016; 115: 65-66.
    1. Liu CH, Kao JH. Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. Int. J. Nanomedicine 2014; 9: 2051-2067.
    1. van der Meer AJ, Veldt BJ, Feld JJ et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-2593.
    1. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann. Intern. Med. 2013; 158: 329-337.

Publication types

MeSH terms

LinkOut - more resources